|Application ||IHC, FC|
|Other Accession||7038, 654591|
|Reactivity||Human, Mouse, Rat|
|Isotype||Mouse / IgG's|
|Clone Names||2H11 + 6E1|
|Calculated MW||660kDa (Dimeric Form)|
|Other Names||Thyroglobulin, Tg, TG|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Thyroglobulin (Thyroidal Cell Marker) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Precursor of the iodinated thyroid hormones thyroxine (T4) and triiodothyronine (T3).|
|Tissue Location||Thyroid gland specific.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Thyroglobulin is a 660kDa dimeric pre-protein with mutiple glycosylation sites. It is produced by and processed within the thyroid gland to produce the hormone thyroxine and triiodothyronine. ĀPrior to forming dimers, thyroglobulin monomers undergo conformational maturation in the endoplasmic reticulation. ĀThe vast majority of follicular carcinomas of the thyroid will give positive immunoreactivity for anti-thyroglobulin even though sometimes only focally. Poorly differentiated carcinomas of the thyroid are frequently anti-thyroglobulin negative. Adenocarcinomas of other-than-thyroid origin do not react with this antibody. This antibody is useful in identification of thyroid carcinoma of the papillary and follicular types. Presence of thyroglobulin in metastatic lesions establishes the thyroid origin of tumor. Anti-thyroglobulin, combined with anti-calcitonin, can identify medullary carcinomas of the thyroid. Furthermore, anti-thyroglobulin, combined with anti-TTF1, can be a reliable marker to differentiate between primary thyroid and lung neoplasms.
Bellet, D, et al. J Clin Endocrin Metab 1983;56:530-533 | Ossendorp FA, et. al. Journal of Immunological Methods, 1989, 120(2):191-200. | Heffess CS et al. Cancer. 2002;95(9):1869-78 | Judkins AR et al. Hum Pathol. 1999;30(11):1373-6 |
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.